KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBITDA: 2009-2024

Historic EBITDA for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to -$92.1 million.

  • Neogenomics' EBITDA fell 27.44% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.9 million, marking a year-over-year decrease of 30.98%. This contributed to the annual value of -$92.1 million for FY2024, which is 14.51% up from last year.
  • As of FY2024, Neogenomics' EBITDA stood at -$92.1 million, which was up 14.51% from -$107.7 million recorded in FY2023.
  • Neogenomics' 5-year EBITDA high stood at -$14.0 million for FY2020, and its period low was -$157.6 million during FY2022.
  • In the last 3 years, Neogenomics' EBITDA had a median value of -$107.7 million in 2023 and averaged -$119.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 748.73% in 2021, then surged by 31.65% in 2023.
  • Neogenomics' EBITDA (Yearly) stood at -$14.0 million in 2020, then crashed by 748.73% to -$118.8 million in 2021, then slumped by 32.73% to -$157.6 million in 2022, then soared by 31.65% to -$107.7 million in 2023, then increased by 14.51% to -$92.1 million in 2024.